Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational studyDamiano Baroncini, G. Coniglio, Paolo Gallo et al.|Neurological Sciences|2022Cited by 32
Mild COVID‐19 infection in a group of teriflunomide‐treated patients with multiple sclerosisVittorio Mantero, Christian Cordano, Damiano Baroncini et al.|Journal of Neurology|2020Cited by 26
Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worseningEmilio Portaccio, Salvatore Lo Fermo, Laura Tudisco et al.|Multiple Sclerosis Journal|2021Cited by 21
Long-term remission of tumefactive relapsing multiple sclerosis after alemtuzumab rescue treatment in an adolescent patientDamiano Baroncini, Mauro Zaffaroni, Pietro Annovazzi et al.|Multiple Sclerosis and Related Disorders|2020Cited by 5
Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumabAlessandra Sottini, Luisa Imberti, Virginia Quaresima et al.|Journal of Neuroimmunology|2023Cited by 1